Targeting Pharmacotherapy to Effectively Manage Eosinophilic Esophagitis

To participate in this activity, please:

Two leading specialists in eosinophilic esophagitis (EoE) explore the increasing disease burden of this underrecognized cause of esophageal dysfunction that affects all age groups worldwide. A type-2 inflammatory condition, EoE is frequently characterized by allergic comorbidity but can also be misdiagnosed as the more common condition of gastroesophageal reflux disease. New and emerging treatments promise to improve outcomes for people with EoE. Drs. Mirna Chehade and Ikuo Hirano share best practices, as well as their own insights and clinical pearls based on their research and clinical practice with children and adults with EoE. This can lead to more expedient diagnosis, better adherence to treatment, and reduced disease burden. This interactive, case-based activity is designed for practicing clinicians. The faculty include lessons learned, quality-of-life considerations, and the near-term outlook for management of people with EoE.  

Course Credit:

1.5 AMA PRA Category 1 CreditsTM
1.5 ANCC Contact Hours
1.5 CA-BRN Contact Hours
0.75 Pharmacology Hours

Dates:

Opens: 2023-03-28
Closes: 2024-03-28

Target Audience:

This activity is intended for gastroenterologists, allergists/immunologists, internists, pediatric subspecialists, physician associates, nurse practitioners, and other clinicians who manage individuals with EoE.

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Accreditation

In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.5 contact hours, including 0.75 pharmacology hours.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.

Additional Content Planners

Donald Gardenier, DNP (Medical Writer)
No significant relationships to disclose.

Heather Jimenez, MSN, FNP-C (Nurse Planner)
No significant relationships to disclose.

Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Mirna Chehade, MD, MPH

    Professor of Pediatrics and Medicine
    Founding Director, Mount Sinai Center for Eosinophilic Disorders
    Icahn School of Medicine at Mount Sinai
    New York, New York

  • Ikuo Hirano, MD

    Professor of Medicine
    Division of Gastroenterology and Hepatology
    Northwestern University Feinberg School of Medicine
    Chicago, Illinois

Learning Objectives

  • Summarize the latest evidence-based recommendations for assessing and diagnosing patients with EoE
  • Identify the pathophysiologic mechanisms and potential treatment targets
  • Initiate evidence-based pharmacologic therapies for EoE

Faculty Disclosures

Mirna Chehade, MD, MPH

Consultant: Adare, Allakos, AstraZeneca, Bristol Myers Squibb, Ellodi, Phathom, Regeneron, Shire, Takeda

Research Support: Adare, Allakos, AstraZeneca, Danone, Ellodi, Regeneron, Shire, Takeda


Ikuo Hirano, MD

Consultant: Allakos, Adare, Arena, AstraZeneca, Bristol Meyers Squibb, Celgene, Ellodi, Nexstone, Phathom, Regeneron, Sanofi, Shire, Takeda

Research Support: Adare, Allakos, Arena, AstraZeneca, Bristol Meyers Squibb, Celgene, Ellodi, Regeneron, Sanofi, Shire, Takeda

Speakers Bureau: Regeneron, Sanofi